German Market Access – Simplified
Everything you need to know in one place, explained in simple terms
Currently, in Germany, free pricing applies in the first year. This means, at the time of launch in the German market, pharmaceutical companies are free to set the price for their product with a new chemical entity (NCE). This price is then valid for the first 12 months from the day of launch.
In July 2021, we had heard that the G-BA had agreed to joint EU HTAs coming to Germany. Now, on 14 December
Biosimilars are biological drugs that are highly similar to another biological medicine, the so-called originator. The biosimilars have no clinically meaningful differences to
Manufacturers of drugs or medical devices can apply for a consultation meeting with the G-BA before submitting a dossier. This consultation offers
On 6 December 2021, Prof. Dr. Karl Lauterbach was announced as the new German health minister. This might mean quite a lot